New Drugs for HDL-C Disorders: the Beginning

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)


Volume 21, 38 Issues, 2014


Download PDF Flyer




Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 5th of 59 in Chemistry & Medicinal
  • 41st of 261 in Pharmacology & Pharmacy
  • 80th of 290 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge
Cambridge
UK
Email: cmc@benthamscience.org

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.07
5 - Year: 4.471

New Drugs for HDL-C Disorders: the Beginning

Author(s): My Ngan Duong and Stephen J. Nicholls

Affiliation: South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia

Abstract

For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable α controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed


Purchase Online Rights and Permissions

Article Details

Volume: 21
First Page: 1
Last Page: 1
Page Count: 1
DOI: 10.2174/0929867321666140414104130
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science